PXDN
Summary: This gene encodes a heme-containing peroxidase that is secreted into the extracellular matrix. It is involved in extracellular matrix formation, and may function in the physiological and pathological fibrogenic response in fibrotic kidney. Mutations in this gene cause corneal opacification and other ocular anomalies, and also microphthalmia and anterior segment dysgenesis. [provided by RefSeq, Aug 2014].
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
peroxidasin | MIM:605158 | Ensembl:ENSG00000130508 | HGNC:HGNC:14966 | PA128394535 | 2p25.3 |
Gene Categories:
DRUGGABLE GENOMEGO terms in PXDN
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
MF | IBA | GO:0004601 | peroxidase activity |
MF | IDA | GO:0004601 | peroxidase activity |
MF | TAS | GO:0004601 | peroxidase activity |
MF | NAS | GO:0005152 | interleukin-1 receptor antagonist activity |
MF | IDA | GO:0005201 | extracellular matrix structural constituent |
MF | IDA | GO:0020037 | heme binding |
MF | IEA | GO:0046872 | metal ion binding |
BP | IEA | GO:0001960 | negative regulation of cytokine-mediated signaling pathway |
BP | NAS | GO:0006955 | immune response |
BP | IEA | GO:0006979 | response to oxidative stress |
BP | IDA | GO:0030198 | extracellular matrix organization |
BP | IDA | GO:0042744 | hydrogen peroxide catabolic process |
BP | IDA | GO:0055114 | oxidation-reduction process |
BP | IEA | GO:0098869 | cellular oxidant detoxification |
CC | TAS | GO:0005576 | extracellular region |
CC | IBA | GO:0005615 | extracellular space |
CC | IDA | GO:0005615 | extracellular space |
CC | IDA | GO:0005783 | endoplasmic reticulum |
CC | IDA | GO:0031012 | extracellular matrix |
CC | HDA | GO:0062023 | collagen-containing extracellular matrix |
CC | HDA | GO:0070062 | extracellular exosome |
Gene expression in normal tissue: PXDN
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in PXDN
Database | Pathway ID | Pathway Des. |
---|---|---|
wikipathways | WP2002 | miR-targeted genes in epithelium - TarBase |
wikipathways | WP2004 | miR-targeted genes in lymphocytes - TarBase |
wikipathways | WP2005 | miR-targeted genes in muscle cell - TarBase |
wikipathways | WP2006 | miR-targeted genes in squamous cell - TarBase |
wikipathways | WP437 | EGF-EGFR Signaling Pathway |
reactome | R-HSA-1474244 | Extracellular matrix organization |
reactome | R-HSA-1474290 | Collagen formation |
reactome | R-HSA-2022090 | Assembly of collagen fibrils and other multimeric structures |
reactome | R-HSA-2243919 | Crosslinking of collagen fibrils |
Gene-Drug: Aster Plot
Drug ID | Drug Name | Model Num. |
---|---|---|
iGMDRD152 | 179324-69-7 | 2 |
iGMDRD61 | Kinetin riboside | 4 |
iGMDRD494 | Neopeltolide | 3 |
iGMDRD483 | SCH-529074 | 1 |
iGMDRD427 | ABT737 | 6 |
iGMDRD889 | Compound 7d-cis | 2 |
iGMDRD229 | B02 | 1 |
iGMDRD420 | Leucascandrolide A | 3 |
iGMDRD506 | Fedratinib | 1 |
iGMDRD577 | BIX01294 | 3 |
iGMDRD562 | Navitoclax | 4 |
iGMDRD188 | Piperlongumine | 2 |
iGMDRD318 | PAC-1 | 7 |
iGMDRD782 | DC-45-A2 | 4 |
iGMDRD255 | SB225002 | 3 |
iGMDRD802 | 4-methylfasudil | 1 |
iGMDRD270 | Ciclosporin | 5 |
iGMDRD474 | Avrainvillamide | 9 |
iGMDRD945 | ML214 | 5 |
iGMDRD435 | BI-2536 | 6 |
iGMDRD883 | CIL55A | 1 |
iGMDRD314 | Tanespimycin | 1 |
iGMDRD351 | GW843682X | 4 |
iGMDRD499 | PDMP | 2 |
iGMDRD219 | Bax channel blocker | 2 |
iGMDRD341 | Triacsin c | 1 |
iGMDRD116 | CD437 | 3 |
iGMDRD150 | RITA | 2 |
iGMDRD424 | Tamatinib | 2 |
iGMDRD512 | nutlin 3 | 9 |
iGMDRD353 | PD0325901 | 2 |
iGMDRD42 | Vorinostat | 3 |
iGMDRD505 | Pevonedistat | 3 |
iGMDRD886 | Compound 1541A | 7 |
iGMDRD552 | AZD-1775 | 6 |
iGMDRD871 | BRD6368 | 5 |
iGMDRD414 | MST-312 | 2 |
iGMDRD872 | BRD7137 | 3 |
iGMDRD481 | Dactolisib | 2 |
iGMDRD77 | Itraconazole | 3 |
iGMDRD289 | Parthenolide | 1 |
iGMDRD6 | AM-580 | 2 |
iGMDRD105 | Triptolide | 5 |
iGMDRD434 | BMS-536924 | 6 |
Gene in drug-gene network: Network Plot

Gene-drug targets distribution
Gene Structure: PDB
Models in PXDN